Kristina Jankovic, Medical Oncology Resident at University Clinical Center Nis, shared a post on X:
“Intratumoral, pembrolizumab and mRNA-2752 for high-risk DCIS : Phase 1 nonrandomized trial
80% response rate
no major systemic toxicities
complete tumor resolution in some possible surgery reduction
Ongoing studies needed.”
